In order to provide the most relevant content to the readers of HealthCare Business News, we're asking you to share a little information about who you are, (it takes two seconds and then you're done).
Register
Novartis Canada partners with Clarius to accelerate diagnosis of psoriatic arthritis
Press releases may be edited for formatting or style | May 29, 2024
Business Affairs
Vancouver, BC, May 27, 2024 – Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems is partnering with Novartis Pharmaceuticals Canada Inc. (Novartis) to provide access to ultrasound for rheumatologists to use for early detection of psoriatic arthritis (PsA). Affecting an estimated 300,000 Canadians, this chronic form of arthritis causes joint inflammation and occurs in 1/3 of people with skin psoriasis1. With improved access to ultrasound technology, rheumatologists will be able to identify diagnostic markers sooner, and may positively impact the timeline to diagnosis for PsA patients.
“We are honoured to collaborate with Novartis Canada on this innovative, focused approach to improving the care of patients suffering from this debilitating disease,” said Clarius President and CEO Ohad Arazi. “This initiative is a perfect example of the benefit of improving access to medical imaging in all areas of medicine. We are delighted that our AI-powered specialty handheld ultrasound scanners are well suited for this purpose.”
The cross-sector partnership is a first for Clarius and aims to increase access to ultrasound devices and training, enabling rheumatologists to see inflammation sooner, improve the time to diagnosis and ultimately improve patient outcomes The Clarius L15 HD3 scanner has been selected for this large scale, commercial implementation due to its ability to automatically provide clear and detailed ultrasound images of superficial anatomy. Easy to learn and use for novices, the scanners connect wirelessly to an AI-powered app on clinicians’ Apple and Android smart devices.
“At Novartis, we recognize the tremendous potential AI holds for our industry and the healthcare landscape at large,” said Mark Vineis, Country President at Novartis Canada. “The partnership with Clarius has the potential to transform PsA detection, with the possibility of scaling to other immunology indications, across specialties and beyond Canada.”
Novartis Canada has collaborated with Canada’s top ultrasound Musculoskeletal (MSK) experts in Canada and members of the Canadian Rheumatology Ultrasound Society (CRUS), to design and lead training sessions for rheumatologists across the country who are enrolled in the ultrasound program. Dr. Mohammed Bardi, a practicing rheumatologist in Vancouver is one of the experts and has been performing ultrasound exams on his patients for the past seven years.
